Buradasınız

Anasayfa » Content

NOVEL NASAL MICROCAPSULAR DELIVERY SYSTEM OF GALANTAMINE HYDROBROMIDE

Journal Name:

  • Advance Research in Pharmaceuticals and Biologicals

Publication Year:

  • 2012

Key Words:

Author Name
Abstract (2. Language): 
The objective of this study was to use spray drying technique to prepare mucoadhesive microcapsules (microparticles) of the antialzheimer drug, Galantamine, in combination with the natural polymer, chitosan, for nasal administration. The effect of different proportion of chitosan on the powder and particle characteristics was also studied. Solutions containing different proportions of chitosans were prepared and spray dried which produced the microparticles having average particle size of 18 μ with the highest production yield of 72%. The size, shape and morphology of the microparticles were also determined by scanning electron microscope. The particle size and particle size distribution of prepared microparticles were determined by projection microscope and the SPAN factor was calculated. The prepared microparticles ware studied for the ex-vivo mucoadhesion and the value found to be more than 180 min. The swelling property of the microparticles was studied and the swelling index was found in the range of 0.68 to 1.42. Solid-state analysis was undertaken using Fourier transform infra-red spectroscopy (FT-IR). The drug release profiles were investigated and the time required to reach maximum solution concentrations (Tmax) was used for comparison. The entrapment efficiency was determined by UV spectrophotometry, with a range of 88-97% drug loading in the microparticles. The microparticles were spherical with a narrow size distribution, irrespective of the formulation. Tmax increased as the proportion of chitosan increased. All the formulation shows the Tmax in the range of 60 to 90 min. Spray drying is a suitable technique for making mucoadhesive microparticles of galantamine and chitosan for nasal administration. The dispersion and release of the drug was affected by the proportion of the chitosan. The nasal administration device for prepared microparticles was successfully developed by the modification of the Rotahaler® device.
Bookmark/Search this post with
FULL TEXT (PDF): 
PDF icon arastrmx_160852_2_pp_268-274.pdf
  • 3
268-274
  • English

REFERENCES

References: 

1. M. I. Ugwoke, R. U. Agu, N. Verbeke, R. Kinget. Nasal
mucoadhesive drug delivery: Background,
applications, trends and future perspectives,
Advanced Drug Delivery Reviews 57: 1640-1665
(2005).
2. H. P. Rang, M. M. Dale, J. M. Ritter, P. K. Moore.
Pharmacology, 5th Edition, pp. 181.
3. Martindale, Sean C. Sweetman. The Complete Drug
Reference, 33rd edition, pp. 855-856.
4. A. E. Pontiroli, A. Calderara, G. Pozza. Intranasal
drug delivery: potential advantages and limitations
from a clinical pharmacokinetic perspective, Clin.
Pharmacokinet. 17: 299–307 (1989).
5. L. Illum. Transport of drugs fromthe nasal cavity to
the central nervous system, Eur. J. Pharm. Sci. 11: 1–
18 (2000).
6. S. S. Davis, L. Illum. Absorption enhancers for nasal
drug delivery, Clin. Pharmacokinet. 42: 1107–1128
(2003).
7. T. J. Aspden, J. D. T. Mason, N. S. Jones, J. Lowe, O.
Skaugrud, L. Illum. Chitosan as a nasal delivery
system: the effect of chitosan on in vitro and in vivo
mucociliary transport rates in human turbinates
and volunteers, J. Pharm. Sci. 86: 509–513 (1997).
8. E. Gavini, A. B. Hegge, G. Rassu, V. Sanna, C. Testa, G.
Pirisino, J. Karlsen, P. Giunchedi. Nasal
administration of Carbamazepine using chitosan
microspheres: In vitro/in vivo studies, International
Journal of Pharmaceutics, 307: 9–15 (2006).
9. J. Varshosaz, H. Sadrai and R. Alinagari. Nasal
delivery of insulin using chitosan microspheres,
Microencapsulation November 2004, vol. 21, no. 7,
761–774.
10. L. Illum. Nasal drug delivery—possibilities,
problems and solutions, Journal of Controlled
Release 87: 187–198 (2003).
11. J. Elversson, A. Millqvist-Fureby, G. Alderborn, U.
Elofsson. Droplet and particle size relationship and
shell thickness of inhalable lactose particles during
spray drying, J. Pharm. Sci. 92: 900–910 (2003).
12. E. Gavini, G. Rassu, C. Muzzarelli, M. Cossu, P.
Giunchedi. Spray-dried microspheres based on
methylpyrrolidinone chitosan as new carrier for
nasal administration of metoclopramide, Eur. J.
Pharm. Sci. 68: 245–252 (2008).
13. L. J. Scott, K. L. Goa. Galantamine: a review of its use
in Alzheimer’s disease, Drugs 60 (5): 1095– 1122
(2000).
14. J. Corey-Bloom. Galantamine: a review of its use in
Alzheimer’s disease and vascular dementia, Int. J.
Clin. Pract. 57 (3): 219– 223 (2003).
15. M. W. Jann, K. L. Shirley, G. W. Small. Clinical
pharmacokinetics and pharmacodynamics of
cholinesterase inhibitors, Clin. Pharmacokinet. 41:
719–739 (2002).
16. J. G. Evans, G. Wilcock, J. Birks. Evidence-based
pharmacotherapy of Alzheimer’s disease, Int. J.
Neuropsychopharmacol. 7: 351–369 (2004).
17. A. Nordberg, A. L. Svensson. Cholinesterase
inhibitors in the treatment of Alzheimer’s disease: a
comparison of tolerability and pharmacology, Drug
Safety 20 (2):
146 (1999).
18. J. J. Sramek, E. J. Frackiewicz, N. R. Cutler. Review of
acetylcholinesterase inhibitor galantamine, Expert
Opin. Investig. Drugs 9 (10): 2393– 2402 (2000).
19. J. Poirier. Evidence that the clinical effects of
cholinesterase inhibitors are related to potency and
targeting of action, Int. J. Clin. Pract., Suppl. 127: 6 –
19 (2002).
20. B. Fulton, P. Benfield. Galanthamine, Drugs Aging 9
(1): 60– 67 (1996).
Shantanu et al., ARPB, 2012; Vol 2 (III) ISSN 2250-0774
(RESEARCH ARTICLE)
274 | P a g e w w w . a r p b . i n f o
21. A. Nordberg, A. L. Svensson. Cholinesterase
inhibitors in the treatment of Alzheimer’s disease: a
comparison of tolerability and pharmacology, Drug
Safety 20 (2): 146 (1999).
22. J. L. Cummings. Use of cholinesterase inhibitors in
clinical practice: evidence-based recommendations,
Am. J. Geriatr. Psychiatry 11 (2): 131– 145 (2003).
23. A. Kays Leonard, A. P. Sileno, C. MacEvilly, C. A.
Foerder, S. C. Quay, H. R. Costantino. Development
of a novel high-concentration galantamine
formulation suitable for intranasal delivery, J.
Pharm. Sci. 94: 1736–1746 (2005).
24. A. Kays Leonard, A. P. Sileno, G. C. Brandt, C. A.
Foerder, S. C. Quay, H. R. Costantino. In vitro
formulation optimization of intranasal galantamine
leading to enhanced bioavailability and reduced
emetic response in vivo, Int. J. Pharm. 335: 138–146
(2007).
25. D. J. V. Drooge, W. L. J. Hinrichs, H. W. Frijlink.
Anomalous dissolution behaviour of tablets
prepared from sugar glass-based solid dispersions,
J. Control. Release 97: 441–452 (2004).
26. E. Gavini, G. Rassu, C. Muzzarelli, M. Cossu, P.
Giunchedi. Spray-dried microspheres based on
methylpyrrolidinone chitosan as new carrier for
nasal administration of metoclopramide, Eur. J.
Pharm. Sci. 86: 245–252 (2008).

Thank you for copying data from http://www.arastirmax.com